Inventor · disambiguated record
Gregg F. Keaney
Also filed as: KEANEY GREGG F
21 granted patents·13 pending applications·73 citations·filing 2007–2025
93Inventor score
Files withCADENT THERAPEUTICS INC10EISAI R&D MAN CO LTD6INFINITY PHARMACEUTICALS INC4NOVARTIS AG4THIRD HARMONIC BIO INC3
Top patents by PatentIndex Score
34 records- 0193US9975886B1Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2018·Granted May 22, 2018·9 cites·2 claims
- 0291US10752633B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Aug 25, 2020·9 cites·5 claims
- 0391US10584131B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Mar 10, 2020·9 cites·2 claims
- 0490US8703448B2Enzymatic transamination of cyclopamine analogsAUSTAD BRIAN C·Filed 2011·Granted Apr 22, 2014·19 cites·37 claims
- 0586US11542264B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·2 claims
- 0686US10351553B2Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·3 cites·6 claims
- 0784US9481669B2Pladienolide pyridine compounds and methods of useEISAI R&D MAN CO LTD·Filed 2015·Granted Nov 1, 2016·7 cites·46 claims
- 0883US9879293B2Enzymatic transamination of cyclopamine analogsINFINITY PHARMACEUTICALS INC·Filed 2016·Granted Jan 30, 2018·3 cites·30 claims
- 0982US2025034145A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1081US8546432B2Tetrazolones as inhibitors of fatty acid synthaseBAHADOOR ADILAH·Filed 2011·Granted Oct 1, 2013·7 cites·35 claims
- 1180US10717728B2Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2019·Granted Jul 21, 2020·1 cites·7 claims
- 1280US2024199617A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1375US9346769B2Tetrazolones as inhibitors of fatty acid synthaseINFINITY PHARMACEUTICALS INC·Filed 2013·Granted May 24, 2016·2 cites·57 claims
- 1474US2024368140A1Certain pladienolide compounds and methods of useEISAI R&D MAN CO LTD·Filed 2024·Application pending·0 cites
- 1572US11926619B2Certain pladienolide compounds and methods of useEISAI R&D MAN CO LTD·Filed 2019·Granted Mar 12, 2024·1 cites·18 claims
- 1672US10774064B2Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2017·Granted Sep 15, 2020·1 cites·17 claims
- 1770US2024317705A1Potassium channel modulatorsNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1867US2025333400A1Certain pladienolide compounds and methods of useEISAI R&D MAN CO LTD·Filed 2025·Application pending·0 cites
- 1967US2021380571A1Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2066US8450350B2Triazoles as inhibitors of fatty acid synthaseBAHADOOR ADILAH·Filed 2011·Granted May 28, 2013·1 cites·37 claims
- 2160US11993586B2Crystalline forms of potassium channel modulatorsNOVARTIS AG·Filed 2019·Granted May 28, 2024·0 cites·13 claims
- 2260US2014371456A1Enzymatic Transamination of Cyclopamine AnalogsAUSTAD BRIAN C·Filed 2014·Application pending·0 cites
- 2359US7928244B2Compounds and methods for inhibiting the interaction of BCL proteins with binding partnersINFINITY DISCOVERY INC·Filed 2007·Granted Apr 19, 2011·0 cites·37 claims
- 2457US2020361915A1Solid state form of pladienolide pyridine compounds and methods of useEISAI R&D MAN CO LTD·Filed 2020·Application pending·0 cites
- 2556US10745387B2Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereofEISAI R&D MAN CO LTD·Filed 2016·Granted Aug 18, 2020·0 cites·26 claims
- 2656US8178690B2Compounds and methods for inhibiting the interaction of BCL proteins with binding partnersCASTRO ALFREDO C·Filed 2011·Granted May 15, 2012·0 cites·15 claims
- 2756US2024254119A1COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORSTHIRD HARMONIC BIO INC·Filed 2023·Application pending·0 cites
- 2854US8609706B2Compounds and methods for inhibiting the interaction of BCL proteins with binding partnersCASTRO ALFREDO C·Filed 2012·Granted Dec 17, 2013·0 cites·14 claims
- 2950US11767319B2Crystalline forms of a selective c-kit kinase inhibitorTHIRD HARMONIC BIO INC·Filed 2021·Granted Sep 26, 2023·0 cites·24 claims
- 3050US11744823B2Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using sameTHIRD HARMONIC BIO INC·Filed 2021·Granted Sep 5, 2023·0 cites·12 claims
- 3149US2013243727A1Triazoles as inhibitors of fatty acid synthaseINFINITY PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3249US2017119734A1Tetrazolones as inhibitors of fatty acid synthaseINFINITY PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3340US2018207138A1Methods for the treatment of tremors by positive modulation of sk channelsCADENT THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3439US2017355708A1Potassium channel modulatorsCADENT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregg F. Keaney files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →